Phase I trial to evaluate the tolerability and pharmacokinetics of single ascending doses of MEM 63908 in healthy adult male volunteers

Trial Profile

Phase I trial to evaluate the tolerability and pharmacokinetics of single ascending doses of MEM 63908 in healthy adult male volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2008

At a glance

  • Drugs Facinicline (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Memory Pharmaceuticals
  • Most Recent Events

    • 30 Sep 2008 Top-line results are expected from the full phase I program in quarter 4 2008, as reported in a Memory Pharmaceuticals media release.
    • 06 Mar 2008 Status changed from recruiting to completed, according to a Memory Pharmaceuticals media release.
    • 13 Sep 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top